EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study

Y Suzuki, A Naganuma, T Hoshino, T Hatanaka, T Ueno, M Namikawa, D Takizawa, H Arai, H Suzuki, H Takagi, H Tojima, Y Yamazaki und 3 weitere

Acta Gastro Enterologica Belgica · 2021

DOI: 10.51821/84.1.357 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Gastro Enterologica Belgica, 2021. Verfasst von Y Suzuki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, 36 Takamatsu-cho, Takasaki, Gunma 370-0829, Japan. Hauptthemen laut MEDLINE: Ascites, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of this retrospective study was to determine whether tolvaptan treatment reduces the amount of albumin administered, volume of ascites removed, and frequency of paracentesis procedures in patients with decompensated cirrhosis with uncontrolled ascites with conventional diuretics. Patients and methods : The control (C) group included patients treated with conventional diuretics. The tolvaptan (T) group included patients treated with both tolvaptan and conventional diuretics. Both groups were matched according to baseline parameters. The amount of albumin administered, volume of ascites removed, and frequency of paracentesis within 30 days of onset of uncontrolled ascites were compared between the two groups.

Results

After matching, 74 patients (C=37, T=37) were included. Baseline parameters (C vs. T group) were as follows : age, 69.5 ± 9.3 vs. 70.4 ± 11.0 years (p = 0.702) ; males, 24 (64.9%) vs. 25 (67.6%) (p = 0.999) ; patients with hepatocellular carcinoma, 17 (45.9%) vs. 18 (48.6%) (p = 0.999) ; serum albumin levels at treatment initiation, 2.76 ± 0.48 vs. 2.73 ± 0.49 g/dL (p = 0.773), and serum creatinine levels at treatment initiation, 1.18 ± 1.23 vs. 1.09 ± 0.48 g/dL (p = 0.679). In the C vs. T groups, respectively, mean amount of albumin administered was 51.0 ± 31.4 vs. 33.4 ± 29.8 g/month (p = 0.016) ; mean volume of ascites removed was 2,905 ± 4,921 vs. 1,824 ± 3,185 mL/month (p = 0.266) ; and mean frequency of paracentesis was 0.92 ± 1.46 vs. 0.89 ± 1.45 procedures (p = 0.937).

Conclusions

Tolvaptan reduced the use of albumin infusion in patients with decompensated cirrhosis and was effective and acceptable for uncontrolled ascites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AscitesLiver NeoplasmsAgedAlbuminsCohort StudiesHumansLiver CirrhosisMaleMiddle AgedPropensity ScoreRetrospective StudiesTolvaptan

Stichwörter der Autor:innen

albumin infusioncirrhosisparacentesistolvaptanuncontrolled ascites

Substanzen

AlbuminsTolvaptan

Autor:innen und Institutionen

  • Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, 36 Takamatsu-cho, Takasaki, Gunma 370-0829, Japan.
  • Department of Gastroenterology, Maebashi Red Cross Hospital, Maebashi, Gunma 371-0014, Japan.
  • Department of Internal Medicine, Isesaki Municipal Hospital, Isesaki, Gunma 372-0817, Japan.
  • Department of Internal Medicine, Kiryu Kosei General Hospital, Kiryu, Gunma 376-0024, Japan.
  • Department of Internal Medicine, Haramachi Red Cross Hospital, Higashiagatsuma, Gunma 377-0882, Japan.
  • Department of Gastroenterology, Kusunoki Hospital, Fujioka, Gunma 375-0024, Japan.

Zitieren

APA

Suzuki, Y., Naganuma, A., Hoshino, T., Hatanaka, T., Ueno, T., Namikawa, M., Takizawa, D., Arai, H., Suzuki, H., Takagi, H., Tojima, H., Yamazaki, Y., Sato, K., Kakizaki, S., & Uraoka, T. (2021). Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study. Acta Gastro Enterologica Belgica. https://doi.org/10.51821/84.1.357

Vancouver

Suzuki Y, Naganuma A, Hoshino T, Hatanaka T, Ueno T, Namikawa M, et al. Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study. Acta Gastro Enterologica Belgica. 2021. doi:10.51821/84.1.357

BibTeX
@article{Suzuki2021,
  author = {Suzuki, Y and Naganuma, A and Hoshino, T and Hatanaka, T and Ueno, T and Namikawa, M and Takizawa, D and Arai, H and Suzuki, H and Takagi, H and Tojima, H and Yamazaki, Y and Sato, K and Kakizaki, S and Uraoka, T},
  title = {Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study},
  journal = {Acta Gastro Enterologica Belgica},
  year = {2021},
  doi = {10.51821/84.1.357}
}
Kostenlos starten →